Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Scaling up ART in Rwanda: the financial and economic costs
Rwanda has been rolling-out free antiretroviral treatment (ART) since 2004. This scale up could only be realised through significantly increased funding to the HIV/AIDS sub-account. Funding grew from US$9 million in 2003 to US$43 million in 2004 (UNAIDS, 2006b) and has continued to grow since this t...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Health Economics Unit
2023
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613200941318144 |
|---|---|
| access_status_str | Open Access |
| author | Karengera, Stephen |
| author2 | Cleary, Susan |
| author_browse | Cleary, Susan Karengera, Stephen |
| author_facet | Cleary, Susan Karengera, Stephen |
| author_sort | Karengera, Stephen |
| collection | Thesis |
| description | Rwanda has been rolling-out free antiretroviral treatment (ART) since 2004. This scale up could only be realised through significantly increased funding to the HIV/AIDS sub-account. Funding grew from US$9 million in 2003 to US$43 million in 2004 (UNAIDS, 2006b) and has continued to grow since this time given increased grants from GFATM and PEPFAR. Although international funding has been pivotal in the initiation of ART roll-out in resource poor settings, national programmes must look inwards for long term sustainability. This raises the question of whether the country will be able to sustain this level of funding once these grants cease ot are significantly reduced. This question could be answered to a large extent if one knew the lifetime costs of providing ART in Rwanda and the capacity of the country to raise domestic revenue. Unfortunately the body of evidence on unit and lifetime costs for providing ART in Rwanda is nonexistent. The study aimed to determine the economic costs of scaling up ART in Rwanda. Costing from the provider's perspective was undertaken based on data from 3,310 patients in 3 ART sites. The health care utilisation and cost data obtained, supplemented by appropriate secondary data, were used to estimate the cost perpatient period and lifetime costs. These were then used to model the costs of scaling up and to explore the financial sustainability of ART in Rwanda. |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/38273 |
| institution | University of Cape Town (South Africa) |
| language | eng |
| last_indexed | 2026-06-10T12:32:21.936Z |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | Health Economics Unit |
| publisherStr | Health Economics Unit |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/38273 Scaling up ART in Rwanda: the financial and economic costs Karengera, Stephen Cleary, Susan public health Rwanda has been rolling-out free antiretroviral treatment (ART) since 2004. This scale up could only be realised through significantly increased funding to the HIV/AIDS sub-account. Funding grew from US$9 million in 2003 to US$43 million in 2004 (UNAIDS, 2006b) and has continued to grow since this time given increased grants from GFATM and PEPFAR. Although international funding has been pivotal in the initiation of ART roll-out in resource poor settings, national programmes must look inwards for long term sustainability. This raises the question of whether the country will be able to sustain this level of funding once these grants cease ot are significantly reduced. This question could be answered to a large extent if one knew the lifetime costs of providing ART in Rwanda and the capacity of the country to raise domestic revenue. Unfortunately the body of evidence on unit and lifetime costs for providing ART in Rwanda is nonexistent. The study aimed to determine the economic costs of scaling up ART in Rwanda. Costing from the provider's perspective was undertaken based on data from 3,310 patients in 3 ART sites. The health care utilisation and cost data obtained, supplemented by appropriate secondary data, were used to estimate the cost perpatient period and lifetime costs. These were then used to model the costs of scaling up and to explore the financial sustainability of ART in Rwanda. 2023-08-24T13:23:39Z 2023-08-24T13:23:39Z 2007 2023-08-23T13:04:30Z Master Thesis Masters MPH http://hdl.handle.net/11427/38273 eng application/pdf Health Economics Unit Faculty of Health Sciences |
| spellingShingle | public health Karengera, Stephen Scaling up ART in Rwanda: the financial and economic costs |
| thesis_degree_str | Master's |
| title | Scaling up ART in Rwanda: the financial and economic costs |
| title_full | Scaling up ART in Rwanda: the financial and economic costs |
| title_fullStr | Scaling up ART in Rwanda: the financial and economic costs |
| title_full_unstemmed | Scaling up ART in Rwanda: the financial and economic costs |
| title_short | Scaling up ART in Rwanda: the financial and economic costs |
| title_sort | scaling up art in rwanda the financial and economic costs |
| topic | public health |
| url | http://hdl.handle.net/11427/38273 |
| work_keys_str_mv | AT karengerastephen scalingupartinrwandathefinancialandeconomiccosts |